BNTX
BioNTech SE
99.10$
+0.6%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 84.4% | 84.9% | 82.1% | 82.2% | 82.5% | 83.5% | 73.8% | 73.6% | 74.2% | 73.4% | 73.7% | 75.2% | |
| 60.8% | 50.7% | 40.3% | 46.7% | 43.0% | 43.3% | 48.1% | 47.5% | 47.3% | 34.9% | 47.2% | 47.9% | |
| 70.9% | 71.9% | 70.4% | 77.8% | 74.6% | 74.5% | 66.6% | 64.9% | 68.1% | 67.5% | 69.5% | 47.9% | |
| 9.0% | 9.4% | 8.6% | 1.3% | 5.3% | 6.8% | 4.8% | 6.7% | 3.3% | 4.5% | 2.9% | 1.2% | |
| 1.9% | 1.6% | 1.6% | 1.5% | 1.4% | 1.3% | 1.2% | 1.1% | 1.1% | 0.5% | 0.5% | 0.5% | |
| 4.2% | – | – | – | – | – | – | – | – | – | – | – | |
| 1.6% | 1.6% | 1.7% | 1.7% | 1.7% | 1.7% | 1.8% | 1.7% | 1.7% | 1.7% | 1.8% | 1.8% | |
| 3.0% | 3.4% | 3.7% | 3.9% | 3.9% | 3.5% | 7.1% | 6.9% | 6.5% | 7.3% | 7.3% | 7.0% | |
| 10.5% | 12.0% | 10.3% | 14.2% | 14.7% | 13.8% | 10.6% | 14.5% | 13.4% | 12.6% | 11.3% | 12.7% | |
| 8.1% | 9.0% | 7.2% | 10.9% | 11.3% | 11.2% | 7.2% | 8.6% | 10.4% | 9.7% | 8.4% | 9.6% | |
| 0.2% | 0.1% | 0.1% | 0.2% | 0.2% | 0.2% | 0.3% | 0.2% | 0.3% | 0.2% | 0.3% | 0.3% | |
| 1.0% | 1.5% | 1.3% | 4.0% | 3.4% | 1.9% | 2.1% | 2.3% | 1.9% | 2.4% | 2.2% | 3.2% | |
| 0.7% | 0.8% | 0.9% | 1.0% | 0.9% | 1.0% | 1.1% | 1.0% | 0.9% | 1.0% | 1.2% | 1.3% | |
| 89.5% | 88.0% | 89.7% | 85.8% | 85.3% | 86.2% | 89.4% | 85.5% | 86.6% | 87.4% | 88.7% | 87.3% | |
| 86.9% | 85.9% | 87.4% | 83.8% | 84.1% | 84.8% | 88.2% | 84.6% | 85.6% | 81.7% | 82.7% | 81.6% | |
| 1.1% | 1.0% | 1.1% | 1.1% | 1.1% | 1.1% | 1.1% | 1.1% | 1.1% | 1.1% | 1.2% | 1.2% |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.